SCHEMBL2883245

SCHEMBL2883245

COc1cccc(S(=O)(=O)N2CC3CCC2C(C(=O)Nc2ccc(OC(C)C)cc2)C3)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ELOVL6 Q9H5J4 20/20 1.00
ELOVL3 Q9HB03 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2883247 1.00 ELOVL6 (1.00) ELOVL6ELOVL3
SCHEMBL2890736 0.90 ELOVL6 (1.00) ELOVL6ELOVL3
SCHEMBL2890735 0.90 ELOVL6 (1.00) ELOVL6ELOVL3
SCHEMBL2892646 0.90 ELOVL6 (1.00) ELOVL6ELOVL3
SCHEMBL2892645 0.90 ELOVL6 (1.00) ELOVL6ELOVL3
SCHEMBL2888966 0.89 ELOVL6 (1.00) ELOVL6ELOVL3
SCHEMBL2888965 0.89 ELOVL6 (1.00) ELOVL6ELOVL3
SCHEMBL2888301 0.86 ELOVL6 (0.83) ELOVL6ELOVL3
SCHEMBL2888304 0.86 ELOVL6 (0.83) ELOVL6ELOVL3
SCHEMBL2891070 0.85 ELOVL6 (1.00) ELOVL6ELOVL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2261210-B1 3-SUBSTITUTED SULFONYL PIPERAZINE DERIVATIVE MSD KK (JP) 2014-10-22 EP disclosed
US-8367698-B2 3-substituted sulfonyl piperidine derivative MSD K.K. (JP) 2013-02-05 US disclosed
US-20120232109-A1 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE NAGASE TSUYOSHI (JP) 2012-09-13 US disclosed
US-8188280-B2 3-substituted sulfonyl piperidine derivative MSD K.K. (JP) 2012-05-29 US disclosed
US-20100331360-A1 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE MSD K.K. (JP) 2010-12-30 US disclosed
EP-2261210-A1 3-SUBSTITUTED SULFONYL PIPERAZINE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331360-A1 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE H1-3, H1-0, H1-2 ELOVL6 1777/4885ELOVL3 1564/4885
US-20120232109-A1 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE H1-3, H1-0, H1-2 ELOVL6 1777/4885ELOVL3 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.